Compare Amazon.com Inc (AMZN) vs BridgeBio Pharma Inc (BBIO) Price & Performance

Amazon (AMZN) trades at $245.34, down 0.69% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings, beating expectations with EPS of $2.78, and shows robust revenue growth, reaching $716.92B in 2025. Operating cash flow remains strong at $139.51B, though heavy investing activities result in modest net cash flow. Analyst sentiment is overwhelmingly positive, with 88.3% recommending Buy and a consensus price target of $320.75.

The outlook for Amazon is favorable, driven by AI advancements in AWS and expanding market penetration. Key risks include intense competition in retail and cloud sectors, high capital expenditures, and macroeconomic pressures. Investors should weigh the strong growth trajectory against these risks, with the stock offering significant upside based on analyst targets.

BridgeBio Pharma (BBIO) trades at $85.89, down 4.75% today but remains near 52-week highs following positive clinical news. The stock shows strong technical momentum with bullish moving averages and support at $85. Fundamentally, revenue grew to $502M in 2025 but net losses widened to -$725M with negative cash flow from operations. Recent news highlights competitor setbacks boosting confidence in Attruby and a $1B preferred equity raise to fund launches.

Outlook hinges on successful drug launches and pipeline execution, with analyst consensus bullish (92% buy ratings) and a $103 price target. Key risks include sustained cash burn, clinical trial outcomes, and high valuation (P/S 28.5) pricing in future success. The stock offers growth potential but requires monitoring of profitability milestones.